GENEPID: A 44-weeks monocentric open study assessing the efficacy and safety of Deucravacitinib in adults with Inflammatory EPidermal GENodermatoses (epidermolysis bullosa simplex and inflammatory congenital ichthyoses)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502879-32-00

Acronym

22-PP-20

Enrollment

Registered

2023-09-25

Start date

2024-01-30

Completion date

Unknown

Last updated

2025-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory EPidermal GENodermatoses

Brief summary

The aim of this study is to assess the efficacy of deucravacitinib in the treatment of patients with EBS-sev and inflammatory congenital ichthyosis

Detailed description

Safety of deucravacitinib treatment, Secondary efficacy and health outcomes measures : severity, itch, pain, quality of life, Compliance, Baseline and functional cytokine profile

Interventions

DRUGdeucravacitinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The aim of this study is to assess the efficacy of deucravacitinib in the treatment of patients with EBS-sev and inflammatory congenital ichthyosis	—

Secondary

Measure	Time frame
Safety of deucravacitinib treatment, Secondary efficacy and health outcomes measures : severity, itch, pain, quality of life, Compliance, Baseline and functional cytokine profile	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026